In contrast, the human monoclonal anti-VEGFR2 antibody Ramucirumab yielded significant survival benefits in patients with previously treated advanced gastric cancer or gastroesophageal junction carcinomas in a phase III clinical trial [193]. Here, KDR is linked to gastric cancer.